Tags : M&A

Therapiva Private Acquires Dr. Reddy’s API Manufacturing Unit Jeedimetla, Hyderabad

Shots: Therapiva to get hold of its all stocks including its related fixed assets, current assets, current liabilities, and employees The division is in response to focus on forming manufacturing operations and optimizing its cost structures and strengthening Therapiva’s API portfolio Therapiva Private Ltd is a joint venture between Omnicare Drugs India Private Limited (subsidiary […]Read More

MeiraGTx Acquires Vector Neurosciences to Strengthen its Neurology Portfolio

Shots: Vector’s acquisition is an all-stock transaction including its novel P-II drug candidate AAV-GAD evaluated for Parkinson’s Disease The acquisition focuses on developing candidate AAV-GAD and providing novel treatments for neurological disorders AAV-GAD is a gene therapy candidate delivering glutamic acid decarboxylase (GAD) gene, currently in P-II for Parkinson’s Disease and has also received FTD […]Read More

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Shots: Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with $60M The focus of the agreement is to improve QoL by providing novel and efficacious therapies for rare conditions including short bowel syndrome(SBS) and rare […]Read More

Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies

Shots: Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s TriNKET technology The agreement is focus on developing and providing immunotherapies using TriNKET technology platform to treat solid malignancies TriNKET technology is based on NK […]Read More

Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for

Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients Tusk’s Spinout Black Belt Therapeutics, will hold […]Read More

Anaeropharma Science and Astellas Pharma Collaborates to Develop Novel Anti-Tumor

Shots: Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further develop and commercialize the develop product Anaeropharma has developed APS001F, a recombinant Bifidobacterium expresses Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, […]Read More

Agilent Technologies Acquires ACEA Biosciences to Strengthen Platform and Capabilities

Shots: ACEA to receive $250M in upfront cash as a total deal value, adding a differentiated portfolio and organizational capabilities in cell analysis Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration, i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth, function, and cellular responses of cells The […]Read More